XML 34 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Jun. 30, 2017
Sep. 30, 2017
Dec. 31, 2016
Sep. 30, 2016
Research and development incentive income and receivable          
Research and development expenses reimbursed (as a percent)     43.50% 45.00%  
Research and development incentive income and receivable          
Balance at the beginning of the period   $ 3,053 $ 3,053    
Australian research and development incentive income $ 961   1,852    
Cash received for 2016 eligible expenses     (3,245)    
Foreign currency translation     234    
Balance at the end of the period 1,894   1,894 $ 3,053  
Overseas research and development incentive income   $ 412   347  
Deferred Offering Costs          
Deferred offering costs       1,402  
Reclassification of deferred offering costs to additional paid-in capital     1,402    
Other Assets          
Other assets 930   930 $ 907  
Deposit related to operating lease for office space in Cambridge, Massachusetts $ 35   $ 35    
Net Loss per Share          
Common stock, outstanding shares 9,395,920   9,395,920 0 0